
D&D Pharmatech Completes Enrollment for 48-Week Phase 2 Trial of DD01 in MASH
D&D Pharmatech a clinical-stage biotechnology company dedicated to the development of disease-modifying therapeutics, has announced the successful completion of patient enrollment for DD01-DN-2, an ongoing Phase 2 clinical trial. This trial is designed to assess the efficacy and safety of…